Mechanisms of Adjuvant Action

Vaccine Adjuvants and Delivery Systems

Volumn , Issue , 2006, Pages 53-79

  Lycke, Nils ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Adjuvant action mechanisms; Combination adjuvants with CTA1 DD; Nontoxic CTA1 DD adjuvant

Indexed keywords

EID: 84889414582     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470134931.ch3     Document Type: Chapter

References (123)

1. Steinman, R.M., Bonifaz, L., Fujii, S., Liu, K., Bonnyay, D., Yamazaki, S., Pack, M., Hawiger, D., Iyoda, T., Inaba, K. & Nussenzweig, M.C. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol 2005, 560, 83-97.
2. Adams, C.L., Kobets, N., Meiklejohn, G.R., Millington, O.R., Morton, A.M., Rush, C.M., Smith, K.M. & Garside, P. Tracking lymphocytes in vivo. Arch Immunol Ther Exp (Warsz) 2004, 52, 173-187.
3. Lindquist, R.L., Shakhar, G., Dudziak, D., Wardemann, H., Eisenreich, T., Dustin, M.L. & Nussenzweig, M.C. Visualizing dendritic cell networks in vivo. Nat Immunol 2005, 5, 1243-1250.
4. Bukreyev, A. & Belyakov, I.M. Expression of immunomodulating molecules by recombinant viruses: Can the immunogenicity of live virus vaccines be improved? Expert Rev Vaccines 2002, 1, 233-245.
5. Vogel, F.R. Immunologic adjuvants for modern vaccine formulations. Ann NY Acad Sci 1995, 754, 153-160.
6. Greenwald, R.J., Freeman, G.J. & Sharpe, A.H. The B7 family revisited. Annu Rev Immunol 2005, 23, 515-548.
7. Crane, I.J. & Forrester, J.V. Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005, 25, 75-102.
8. Raine, T., Zaccone, P., Dunne, D.W. & Cooke, A. Can helminth antigens be exploited therapeutically to downregulate pathological Th1 responses? Curr Opin Invest Drugs 2004, 5, 1184-1191.
9. Bluestone, J.A. & Abbas, A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3, 253-257.
10. Baecher-Allan, C. & Anderson, D.E. Immune regulation in tumor-bearing hosts. Curr Opin Immunol 2006, 18, 214-219.
11. Berrih-Aknin, S., Fuchs, S. & Souroujon, M.C. Vaccines against myasthenia gravis. Expert Opin Biol Ther 2005, 5, 983-995.
12. Matzinger, P. & Guerder, S. Does T-cell tolerance require a dedicated antigenpresenting cell? Nature 1989, 338, 74-76.
13. Underhill, D.M. & Ozinsky, A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002, 14, 103-110.
14. Barton, G.M. & Medzhitov, R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 2002, 14, 380-338.
15. Lauw, F.N., Caffrey, D.R. & Golenbock, D.T. Of mice and man: TLR11 (finally) finds profilin. Trends Immunol 2005, 26, 509-511.
16. Inohara, N. & Nunez, G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003, 3, 371-382.
17. Strober, W., Murray, P.J., Kitani, A. & Watanabe, T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006, 6, 9-20.
18. Murray, P.J. NOD proteins: an intracellular pathogen-recognition system or signal transduction modifiers? Curr Opin Immunol 2005, 17, 352-358.
19. Ricciardi-Castagnoli, P. & Granucci, F. Opinion: interpretation of the complexity of innate immune responses by functional genomics. Nat Rev Immunol 2002, 2, 881-889.
20. Sharpe, A. Analysis of costimulation in vivo using transgenic and knockout mice. Curr Opin Immunol 1995, 7, 389-395.
21. Liang, Y., Zhou, Y. & Shen, P. NF-kappaB and its regulation on the immune system. Cell Mol Immunol 2004, 1, 343-350.
22. Holmgren, J., Czerkinsky, C., Lycke, N. & Svennerholm, A.-M. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier and adjuvant. Am J Med Hyg 1994, 50, 42-54.
23. Lycke, N. Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 2005, 5, 591-597.
24. Duverger, A., Jackson, R.J., van Ginkel, F.W., Fischer, R., Tafaro, A., Leppla, S.H., Fujihashi, K., Kiyono, H., McGhee, J.R. & Boyaka, P.N. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 2006, 176, 1776-1783.
25. He, J., Gurunathan, S., Iwasaki, A., Ash-Shaheed, B. & Kelsall, B.L. Primary role for Gi protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses. J Exp Med 2000, 191, 1605-1610.
26. Ryan, M., McCarthy, L., Rappuoli, R., Mahon, B.P., & Mills, K.H. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int Immunol 1998, 10, 651-662.
27. Hou, W., Wu, Y., Sun, S., Shi, M., Sun, Y., Yang, C., Pei, G., Gu, Y., Zhong, C. & Sun, B. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J Immunol 2003, 170, 1728-1736.
28. Hornquist, E. & Lycke, N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol 1993, 23, 2136-2143.
29. Yamamoto, M., Kiyono, H., Kweon, M.N., Yamamoto, S., Fujihashi, K., Kurazono, H., Imaoka, K., Bluethmann, H., Takahashi, I., Takeda, Y., Azuma, M. & McGhee, J.R. Enterotoxin adjuvants have direct effects on T cells and antigenpresenting cells that result in either interleukin-4-dependent or-independent immune responses. J Infect Dis 2000, 182, 180-190.
30. Bonifaz, L.C., Bonnyay, D.P., Charalambous, A., Darguste, D.I., Fujii, S., Soares, H., Brimnes, M.K., Moltedo, B., Moran, T.M. & Steinman, R.M. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199, 815-824.
31. Getahun, A. & Heyman, B. How antibodies act as natural adjuvants. Immunol Lett 2006, 104, 38-45.
32. Lehner, T. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 2003, 21(Supp 2), S68-S76.
33. Cohen-Sfady, M., Nussbaum, G., Pevsner-Fischer, M., Mor, F., Carmi, P., Zanin-Zhorov, A., Lider, O. & Cohen, I.R. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol 2005, 175, 3594-3602.
34. Lee, Y., Haas, K.M., Gor, D.O., Ding, X., Karp, D.R., Greenspan, N.S., Poe, J.C. & Tedder, T.F. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J Immunol 2005, 175, 8011-8023.
35. Edelman, R. Adjuvants for the future. In New Generation Vaccines, 2nd ed., Woodrow, G.C., Levine, M.M., Kaper, J.B. & Cobon, G.S., Eds., Marcel Dekker, New York, 1997, pp. 173-192.
36. Jackson, D.C., Lau, Y.F., Le, T., Suhrbier, A., Deliyannis, G., Cheers, C., Smith, C., Zeng, W. & Brown, L.E. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004, 101, 15440-15445.
37. Bergfors, E., Bjorkelund, C. & Trollfors, B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr 2005, 164, 691-697.
38. Gupta, R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32, 155-172.
39. Germain, R.N. & Jenkins, M.K. In vivo antigen presentation. Curr Opin Immunol 2004, 16, 120-125.
40. Perrier, P., Martinez, F.O., Locati, M., Bianchi, G., Nebuloni, M., Vago, G., Bazzoni, F., Sozzani, S., Allavena, P. & Mantovani, A. Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-activating chemokine, CXC chemokine ligand 13. J Immunol 2004, 172, 7031-7042.
41. Moynagh, P.N. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005, 26, 469-476.
42. Moynagh, P.N. The NF-kappaB pathway. J Cell Sci 2005, 118, 4589-4592.
43. Ulrich, J.T. MPLr immunostimulant: adjuvant formulations. In Vaccine Adjuvants: Preparation Methods and Research Protocols, O'Hagan, D.T., Ed., Humana Press, Totowa, NJ, 2000, pp. 273-282.
44. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20, 709-760.
45. Wagner, H. The immunobiology of the TLR9 subfamily. Trends Immunol 2004, 25, 381-386.
46. Chu, N.R., DeBenedette, M.A., Stiernholm, B.J.N., Barber, B.H. & Watts, T.H. Role of IL-12 and 4-1 BB ligand in cytokine production by CD28+ and CD28-T cells. J Immunol 1997, 158, 3081-3089.
47. van Duin, D., Medzhitov, R. & Shaw, A.C. Triggering TLR signaling in vaccination. Trends Immunol 2006, 27, 49-55.
48. Xie, H., Gursel, I., Ivins, B.E., Singh, M., O'Hagan, D.T., Ulmer, J.B. & Klinman, D. M. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 2005, 73, 828-833.
49. Adamsson, J., Lindblad, M., Lundqvist, A., Kelly, D., Holmgren, J. & Harandi, A. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin. J Immunol 2006, 15, 4902-4913.
50. Moschos, S.A., Bramwell, V.W., Somavarapu, S. & Alpar, H.O. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine 2006, 24, 1081-1086.
51. Gobec, S., Sollner-Dolenc, M., Urleb, U., Wraber, B., Simcic, S. & Filipic, M. Modulation of cytokine production by some phthalimido-desmuramyl dipeptides and their cytotoxicity. Farmaco 2004, 59, 345-352.
52. Tada, H., Aiba, S., Shibata, K., Ohteki, T. & Takada, H. Synergistic effect of NOD1 and NOD2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 2005, 73, 7967-7976.
53. Fritz, J.H., Girardin, S.E., Fitting, C., Werts, C., Mengin-Lecreulx, D., Caroff, M., Cavaillon, J.M., Philpott, D.J. & Adib-Conquy, M. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1-and NOD2-activating agonists. Eur J Immunol 2005, 35, 2459-2470.
54. Kersten, G.F. & Crommelin, D.J. Liposomes and ISCOMs. Vaccine 2003, 21, 915-920.
55. Morein, B., Sundquist, B., Höglund, S., Dalsgaard, K. & Osterhaus, A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308, 457-462.
56. Sanders, M.T., Brown, L.E., Deliyannis, G. & Pearse, M.J. ISCOM-based vaccines: the second decade. Immunol Cell Biol 2005, 83, 119-128.
57. Mowat, A.M. Dendritic cells and immune responses to orally administered antigens. Vaccine 2005, 23, 1797-1799.
58. Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R.N. & Berzofsky, J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344, 873-875.
59. Smith, R.E., Donachie, A.M., Grdic, D., Lycke, N. & Mowat, A.M. Immunestimulating complexes induce an IL-12-dependent cascade of innate immune responses. J Immunol 1999, 162, 5536-5546.
60. Davidsen, J., Rosenkrands, I., Christensen, D., Vangala, A., Kirby, D., Perrie, Y., Agger, E.M. & Andersen, P. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005, 1718, 22-31.
61. Siegrist, C.A., Pihlgren, M., Tougne, C., Efler, S.M., Morris, M.L., Al Adhami, M.J., Cameron, D.W., Cooper, C.L., Heathcote, J., Davis, H.L. & Lambert, P.H. Coadministration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004, 23, 615-622.
62. Kim, S.K., Ragupathi, G., Cappello, S., Kagan, E. & Livingston, P.O. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000, 19, 530-537.
63. Olszewska, W., Partidos, C.D. & Steward, M.W. Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. Infect Immun 2000, 68, 4923-4929.
64. Moschos, S.A., Bramwell, V.W., Somavarapu, S. & Alpar, H.O. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. Vaccine 2005, 23, 1923-1930.
65. Berry, L.J., Hickey, D.K., Skelding, K.A., Bao, S., Rendina, A.M., Hansbro, P.M., Gockel, C.M. & Beagley, K.W. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 2004, 72, 1019-1028.
66. Baudner, B.C., Giuliani, M.M., Verhoef, J.C., Rappuoli, R., Junginger, H.E. & Giudice, G.D. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 2003, 21, 3837-3844.
67. Mowat, A.M., Parker, L.A., Beacock-Sharp, H., Millington, O.R. & Chirdo, F. Oral tolerance: overview and historical perspectives. Ann N Y Acad Sci 2004, 1029, 1-8.
68. Lycke, N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol 2004, 6, 23-32.
69. Salmond, R.J., Pitman, R.S., Jimi, E., Soriani, M., Hirst, T.R., Ghosh, S., Rincon, M. & Williams, N.A. CD8+ T cell apoptosis induced by Escherichia coli heatlabile enterotoxin B subunit occurs via a novel pathway involving NF-kappaBdependent caspase activation. Eur J Immunol 2002, 32, 1737-1747.
70. Lavelle, E.C., Jarnicki, A., McNeela, E., Armstrong, M.E., Higgins, S.C., Leavy, O. & Mills, K.H. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J Leukoc Biol 2004, 75, 756-763.
71. Stevceva, L. & Ferrari, M.G. Mucosal adjuvants. Curr Pharm Des 2005, 11, 801-811.
72. Childers, N.K., Miller, K.L., Tong, G., Llarena, J.C., Greenway, T., Ulrich, J.T. & Michalek, S.M. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun 2000, 68, 5509-5516.
73. Harandi, A.M. & Holmgren, J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr Opin Investig Drugs 2004, 5, 141-145.
74. Mowat, A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003, 3, 331-341.
75. O'Hagan, D.T., MacKichan, M.L., & Singh, M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001, 18, 69-85.
76. Eriksson, A.M., Schon, K.M. & Lycke, N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 2004, 173, 3310-3319.
77. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5, 987-995.
78. Itano, A.A., McSorley, S.J., Reinhardt, R.L., Ehst, B.D., Ingulli, E., Rudensky, A.Y. & Jenkins, M.K. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003, 19, 47-57.
79. Pulendran, B., Banchereau, J., Maraskovsky, E. & Maliszewski, C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001, 22, 41-47.
80. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J.V., Steinman, R.M., & Nussenzweig, M.C. Dendritic cells induce peripheral T cell unresponsivenes under steady state conditions in vivo. J Exp Med 2001, 194, 769-779.
81. Mempel, T.R., Henrickson, S.E. & Von Andrian, U.H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004, 427, 154-159.
82. Fan, E., O'Neal, C.J., Mitchell, D.D., Robien, M.A., Zhang, Z., Pickens, J.C., Tan, X.J., Korotkov, K., Roach, C., Krumm, B., Verlinde, C.L., Merritt, E.A. & Hol, W.G. Structural biology and structure-based inhibitor design of cholera toxin and heatlabile enterotoxin. Int J Med Microbiol 2004, 294, 217-223.
83. De Haan, L. & Hirst, T.R. Cholera toxin: a paradigm for multifunctional engagement of cellular mechanisms (review). Mol Membr Biol 2004, 21, 77-92.
84. Miller, C.E., Majewski, J., Faller, R., Satija, S. & Kuhl, T.L. Cholera toxin assault on lipid monolayers containing ganglioside GM1. Biophys J 2004, 86, 3700-3708.
85. Soriani, M., Bailey, L. & Hirst, T.R. Contribution of the ADP-ribosylating and receptor-binding properties of cholera-like enterotoxins in modulating cytokine secretion by human intestinal epithelial cells. Microbiology 2002, 148, 667-676.
86. Rappuoli, R., Pizza, M., Douce, G. & Dougan, G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 1999, 20, 493-500.
87. Kawamura, Y.I., Kawashima, R., Shirai, Y., Kato, R., Hamabata, T., Yamamoto, M., Furukawa, K., Fujihashi, K., McGhee, J.R., Hayashi, H. & Dohi, T. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation. Eur J Immunol 2003, 33, 3205-3512.
88. Freytag, L.C. & Clements, J.D. Mucosal adjuvants. Vaccine 2005, 23, 1804-1813.
89. Giuliani, M.M., Del Giudice, G., Giannelli, V., Dougan, G., Douce, G., Rappuoli, R. & Pizza, M. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity [in process citation]. J Exp Med 1998, 187, 1123-1132.
90. Sandvig, K., Spilsberg, B., Lauvrak, S.U., Torgersen, M.L., Iversen, T.G. & van Deurs, B. Pathways followed by protein toxins into cells. Int J Med Microbiol 2004, 293, 483-490.
91. Zhu, X., Kim, E., Boman, A.L., Hodel, A., Cieplak, W. & Kahn, R.A. ARF binds the C-terminal region of the Escherichia coli heat-labile toxin (LTA1) and competes for the binding of LTA2. Biochemistry 2001, 40, 4560-4568.
92. Massol, R.H., Larsen, J.E., Fujinaga, Y., Lencer, W.I. & Kirchhausen, T. Cholera toxin toxicity does not require functional Arf6-and dynamin-dependent endocytic pathways. Mol Biol Cell 2004, 15, 3631-3641.
93. Stevens, L.A., Moss, J., Vaughan, M., Pizza, M. & Rappuoli, R. Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADPribosyltransferase activity and interaction with ADP-ribosylation factors. Infect Immun 1999, 67, 259-265.
94. Tsai, B., Rodighiero, C., Lencer, W. I. & Rapoport, T.A. Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin. Cell 2001, 104, 937-948.
95. Gardby, E., Wrammert, J., Schon, K., Ekman, L., Leanderson, T. Lycke, N. Strong differential regulation of serum and mucosal IgA responses as revealed in CD28-deficient mice using cholera toxin adjuvant. J Immunol 2003, 170, 55-63.
96. Chen, X., Winkler-Pickett, R.T., Carbonetti, N.H., Ortaldo, J.R., Oppenheim, J.J. & Howard, O.M. Pertussis toxin as an adjuvant suppresses the number and function of CD4(+)CD25(+) T regulatory cells. Eur J Immunol 2006, 36, 671-680.
97. Gagliardi, M.C., Sallusto, F., Marinaro, M., Langenkamp, A., Lanzavecchia, A. & De Magistris, M.T. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 2000, 30, 2394-2403.
98. Gagliardi, M.C. & De Magistris, M.T. Maturation of human dendritic cells induced by the adjuvant cholera toxin: role of cAMP on chemokine receptor expression. Vaccine 2003, 21, 856-861.
99. Holmgren, J., Harandi, A.M. & Czerkinsky, C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev Vaccines 2003, 2, 205-217.
100. Grdic, D., Ekman, L., Schon, K., Lindgren, K., Mattsson, J., Magnusson, K.E., Ricciardi-Castagnoli, P. & Lycke, N. Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin. J Immunol 2005, 175, 5192-5202.
101. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat Med 2005, 11, S45-S53.
102. Kaper, J.B., Lockman, H., Baldini, M.M. & Levine, M.M. A recombinant live oral cholera vaccine. Nature 1984, 308, 655-658.
103. Fujihashi, K., Koga, T., van Ginkel, F.W., Hagiwara, Y. & McGhee, J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002, 20, 2431-2438.
104. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R.T., Linder, T., Spyr, C. & Steffen, R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350, 896-903.
105. Glueck, R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 2001, 20, (Suppl 1), S42-S44.
106. Douce, G., Giuliani, M.M., Giannelli, V., Pizza, M.G., Rappuoli, R. & Dougan, G. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli [in process citation]. Vaccine 1998, 16, 1065-1073.
107. Kweon, M.N., Yamamoto, M., Watanabe, F., Tamura, S., Van Ginkel, F.W., Miyauchi, A., Takagi, H., Takeda, Y., Hamabata, T., Fujihashi, K., McGhee, J.R. & Kiyono, H. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis 2002, 186, 1261-1269.
108. Agren, L.C., Ekman, L., Lowenadler, B. & Lycke, N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997, 158, 3936-3946.
109. Uhlen, M., Guss, B., Nilsson, B., Gatenbeck, S., Philipson, L. & Lindberg, M. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem 1984, 259, 1695-1702.
110. Agren, L., Lowenadler, B. & Lycke, N. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol Cell Biol 1998, 76, 280-287.
111. Levine, M.M., Black, R.E., Clements, M.L., Lanata, C., Sears, S., Honda, T., Young, C.R. & Finkelstein, R.A. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun 1984, 43, 515-522.
112. Agren, L.C., Ekman, L., Lowenadler, B., Nedrud, J.G. & Lycke, N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 1999, 162, 2432-2440.
113. Agren, L., Sverremark, E., Ekman, L., Schon, K., Lowenadler, B., Fernandez, C. & Lycke, N. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2-and germinal center-promoting effects. J Immunol 2000, 164, 6276-6286.
114. van Ginkel, F.W., Jackson, R.J., Yuki, Y. & McGhee, J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165, 4778-4782.
115. Choi, A.H., McNeal, M.M., Flint, J.A., Basu, M., Lycke, N.Y., Clements, J.D., Bean, J.A., Davis, H.L., McCluskie, M.J., VanCott, J.L. & Ward, R.L. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 2002, 20, 1733-1740.
116. Akhiani, A.A., Stensson, A., Schon, K. & Lycke, N. The nontoxic CTA1-DD adjuvant enhances protective immunity against helicobacter pylori infection following mucosal immunization. Scand J Immunol 2006, 63, 97-105.
117. De Filette, M., Ramne, A., Birkett, A., Lycke, N., Lowenadler, B., Min Jou, W., Saelens, X. & Fiers, W. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24, 544-551.
118. Cong, Y., Weaver, C. & Elson, C. The mucosal adjuvanticity of cholera toxin involves enhancement of co-stimulatory activity by selective up-regulation of B7.2 expression. J Immunol 1997, 159, 5301.
119. Mowat, A.M., Donachie, A.M., Jagewall, S., Schon, K., Lowenadler, B., Dalsgaard, K., Kaastrup, P. & Lycke, N. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J Immunol 2001, 167, 3398-3405.
120. Helgeby, A., Robson, N.C., Donachie, A.M., Beackock-Sharp, H., Lovgren, K., Schon, K., Mowat, A. & Lycke, N.Y. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol 2006, 176, 3697-3706.
121. Robson, N.C., Beacock-Sharp, H., Donachie, A.M. & Mowat, A.M. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology 2003, 110, 95-104.
122. Katakai, T., Hara, T., Lee, J.H., Gonda, H., Sugai, M. & Shimizu, A. A novel reticular stromal structure in lymph node cortex: an immuno-platform for interactions among dendritic cells, T cells and B cells. Int Immunol 2004, 16, 1133-1142.
123. Galibert, L., Diemer, G.S., Liu, Z., Johnson, R.S., Smith, J.L., Walzer, T., Comeau, M.R., Rauch, C.T., Wolfson, M.F., Sorensen, R.A., Van der Vuurst de Vries, A.R., Branstetter, D.G., Koelling, R.M., Scholler, J., Fanslow, W.C., Baum, P.R., Derry, J.M. & Yan, W. Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule. J Biol Chem 2005, 280, 21955-21964.